Granite Point Capital Management, L.P. Uni Qure N.V. Transaction History

Granite Point Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$18.12 - $27.32 $706,680 - $1.07 Million	39,000 Added 86.67%	84,000 $1.9 Million
Q3 2022 Nov 04, 2022	SELL	$16.98 - $25.54 $254,700 - $383,100	-15,000 Reduced 25.0%	45,000 $844,000
Q2 2022 Aug 05, 2022	BUY	$13.15 - $20.45 $789,000 - $1.23 Million	60,000 New	60,000 $1.12 Million

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.